The Future Of Rebates: MedPAC Will Be Watching For Pricing Law Impacts
The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on actual prescription drug spending – but immediate recommendations may not be viable given the changes coming from implementation of the Inflation Reduction Act.
You may also be interested in...
New GAO recommendations springing from recent Medicare Part D cost and access trends related to rebates may not be relevant going forward because the IRA price negotiation program and benefit redesign will significantly change the landscape, HHS says.
Medicare Payment Advisory Commission appears ready to open yet another front in investigations and policy recommendations regarding PBM practices as it continues to dig into newly available data on rebates in the Part D program.
Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.